December 20, 2024

Victoria Stodden to receive Humboldt Research Award

Victoria Stodden to receive Humboldt Research Award

Victoria Stodden, statistician and associate professor at the Daniel J. Epstein Department of Industrial and Systems Engineering at the University of Southern California, has been selected to receive a prestigious Humboldt Research Award.

Granted by the Alexander von Humboldt Foundation, the award is bestowed on internationally leading researchers in recognition of outstanding academic achievements. A key goal of the award is to facilitate international scientific collaboration, as awardees spend up to a year at research institutions in Germany, where they collaborate with specialist colleagues. 

“This is a very exciting step for me. The award recognizes more than a single result or paper, it is an appreciation of my entire research agenda,” said Stodden.

Stodden, who has been serving as vice-chair of the HITS Scientific Advisory Board since 2022, is a global leader in the field of reproducibility in computational and data science, exploring how the reliability and replicability of increasingly sophisticated computational approaches can be ensured. Her work also addresses standards of openness for data and code sharing, legal and policy barriers to disseminating reproducible research, and scientific publishing practices.

“Victoria Stodden’s research and expertise are of utmost importance to HITS, where computational and data science take center stage,” says Tilmann Gneiting, Scientific Director at HITS and leader of the Computational Statistics group at HITS and Karlsruhe Institute of Technology (KIT). Stodden’s research agenda also plays crucial roles at the KIT Graduate School Computational and Data Science (KCDS) where Stodden will serve as a visiting professor, supported by a KIT International Excellence Fellowship. “We very much look forward to welcoming Victoria Stodden in Heidelberg and Karlsruhe from January 2025 onwards,” say Gneiting and co-host Melanie Schienle at KIT.

Stodden earned her Ph.D. in statistics from Stanford University, and her law degree from Stanford Law School. She has served on various committees of the US National Academies of Science, Engineering, and Medicine and co-chaired the US National Science Foundation’s Advisory Committee for CyberInfrastructure. Her membership in the HITS Scientific Advisory Board will be suspended during the research stay in Germany.

Press Contact:
Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies

Scientific Contact:
Prof. Dr. Tilmann Gneiting
Computational Statistics Group
Heidelberg Institute for Theoretical Studies

Our latest News

discover more
Antitrust hurdle cleared: Important milestone on the way to the Heidelberg-Mannheim hospital network

Antitrust hurdle cleared: Important milestone on the way to the Heidelberg-Mannheim hospital network

At the request of Heidelberg University Hospital, the Ministry of Social Affairs, Health and Integration has confirmed that the merger of the two university hospitals in Heidelberg and Mannheim is deemed necessary to improve hospital care and that the merger does not conflict with any other competition law regulations. Press release from the Ministry of […]

Childhood brain tumors develop early in highly specialized nerve cells

Childhood brain tumors develop early in highly specialized nerve cells

Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have now published their findings in the journal Nature. They […]

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA’s proprietary ADC technology with OmniAb’s antibody discovery technology for novel therapies targeting solid tumors. ZURICH, SWITZERLAND, May 5, 2025 — VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp